Researchers launch Ebola treatment study as Congo outbreak worsens

The World Health Organization says the first participant has enrolled in a new clinical trial testing Ebola treatments in eastern Congo, marking a rare attempt to study potential therapies in the middle of an active outbreak that continues to worsen.

The study is evaluating remdesivir, an antiviral drug, and MBP134, an antibody-based treatment designed to target Ebola viruses including the Bundibugyo strain. AP reported that the trial began on July 2, 2026, after months of preparation by international partners.

WHO said the trial is randomized and will track survival over 28 days. For now, it is limited to one Ebola treatment center in Ituri province because violence and access problems are making it difficult to operate more broadly.

What the trial is testing

The new study is focused on one of the harder questions in the outbreak response: whether candidate treatments can improve survival when they are used during a fast-moving epidemic rather than in a more controlled setting.

Remdesivir is being tested as an antiviral. MBP134 is being studied as an antibody treatment aimed at Ebola viruses, including Bundibugyo, the strain linked to the current outbreak in eastern Congo.

AP reported that the effort is supported by the World Health Organization, Congo's National Biomedical Research Institute, Oxford University and other international health groups. The drug supplies came from Gilead and the U.S. government.

The trial is a notable escalation from the response phase that came before it. Earlier coverage had framed the study as something that could begin only after approvals and security conditions allowed. Now, the first participant has been enrolled.

Why the outbreak is so severe

The outbreak is unfolding in a part of Congo where health workers have faced repeated access problems. WHO said the study is initially confined to a single site because of the security environment in eastern Congo and the difficulty of moving safely through the area.

Tedros Adhanom Ghebreyesus, the WHO director-general, said more than 1,400 people had been diagnosed and 438 had died. He also said more than 200 people had recovered with supportive care, but that better treatment options are still needed.

That toll helps explain why the trial matters even before results are known. Supportive care can help patients survive, but the outbreak's death count shows that current tools are not enough on their own.

Bundibugyo Ebola also matters because AP said there is no specific approved treatment or vaccine for this outbreak. That leaves researchers trying to test therapies under emergency conditions while the epidemic is still active.

The combination of a severe outbreak, a less common Ebola strain and unstable field conditions makes the trial both scientifically important and operationally fragile.

Why Ituri is the starting point

The study is beginning at one Ebola treatment center in Ituri province. That limited footprint reflects the reality on the ground rather than the scale researchers may ultimately want.

Violence and access constraints are restricting how many sites can safely participate, how quickly patients can be enrolled and how easily teams can follow participants after treatment starts.

Those limits also shape what the study can prove. A broader network would make it easier to gather more data, but it would also require more security, more logistics and more reliable movement for staff, supplies and patients.

For now, the first site is the place where the trial can actually operate. That makes the opening enrollment a practical milestone as much as a scientific one.

The launch also signals that health authorities are willing to test therapies even while the outbreak is still unfolding, rather than waiting for the situation to stabilize.

What comes next

The main near-term questions are operational. Researchers and health officials will be watching enrollment numbers, whether the study can expand beyond the first treatment center and whether more protocol details are released.

Another open issue is whether the trial can maintain reliable follow-up in a conflict-affected area. That will matter for any safety data, survival analysis and future decisions about whether the treatments should be used more broadly.

If either drug shows benefit, the implications would extend beyond the single study site. Effective treatment could make a difference in a region where access to care is already constrained.

For now, the launch gives the outbreak response a new scientific track alongside the emergency public health work already under way. The immediate test is whether the trial can keep enrolling patients safely enough to produce usable evidence.

AP said the study will follow patients for 28 days. The next results are not immediate, but the enrollment itself makes clear that the search for a better Ebola treatment is now happening inside the outbreak, not just alongside it.